Optimizing Treatments for Heart Failure During Hospitalization
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 184
- 试验地点
- 2
- 主要终点
- Prescription score
研究概览
简要总结
Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year.
Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2).
Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality.
The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient ≥ 18 years
- •Hospitalized (≥24h) for decompensated heart failure in cardiology.
排除标准
- •Patient opposition participation in research and use of data.
结局指标
主要结局
Prescription score
时间窗: During hospitalisation for decompensated heart failure (up to 10 days)
Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2.
次要结局
- serum concentration of creatinine(During hospitalisation for decompensated heart failure (up to10 days))
- serum concentration of potassium(During hospitalisation for decompensated heart failure (up to 10 days))
- Concentration of hemoglobin(During hospitalisation for decompensated heart failure (up to 10 days))
- All cause Death(6 months)
- Rate of hospitalization for heart failure(6 months)
研究者
Pr. Nicolas GIRERD
coordinating investigator
Central Hospital, Nancy, France